These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

482 related items for PubMed ID: 19197792

  • 1. Treatment of multiresistant Acinetobacter baumannii infections.
    Pachón J, Vila J.
    Curr Opin Investig Drugs; 2009 Feb; 10(2):150-6. PubMed ID: 19197792
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic options for Acinetobacter baumannii infections.
    Vila J, Pachón J.
    Expert Opin Pharmacother; 2008 Mar; 9(4):587-99. PubMed ID: 18312160
    [Abstract] [Full Text] [Related]

  • 3. Treatment of Acinetobacter infections.
    Michalopoulos A, Falagas ME.
    Expert Opin Pharmacother; 2010 Apr; 11(5):779-88. PubMed ID: 20210684
    [Abstract] [Full Text] [Related]

  • 4. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains.
    Li J, Nation RL, Owen RJ, Wong S, Spelman D, Franklin C.
    Clin Infect Dis; 2007 Sep 01; 45(5):594-8. PubMed ID: 17682994
    [Abstract] [Full Text] [Related]

  • 5. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.
    Song JY, Kee SY, Hwang IS, Seo YB, Jeong HW, Kim WJ, Cheong HJ.
    J Antimicrob Chemother; 2007 Aug 01; 60(2):317-22. PubMed ID: 17540672
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa.
    Rice LB.
    Clin Infect Dis; 2006 Sep 01; 43 Suppl 2():S100-5. PubMed ID: 16894511
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, Dukart G, Cooper A, Dartois N, Gandjini H, Orrico R, Ellis-Grosse E, 309 Study Group.
    J Antimicrob Chemother; 2008 Sep 01; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [Abstract] [Full Text] [Related]

  • 12. Antibacterial activity of carbapenem-based combinations againts multidrug-resistant Acinetobacter baumannii.
    Pongpech P, Amornnopparattanakul S, Panapakdee S, Fungwithaya S, Nannha P, Dhiraputra C, Leelarasamee A.
    J Med Assoc Thai; 2010 Feb 01; 93(2):161-71. PubMed ID: 20301995
    [Abstract] [Full Text] [Related]

  • 13. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections.
    Saballs M, Pujol M, Tubau F, Peña C, Montero A, Domínguez MA, Gudiol F, Ariza J.
    J Antimicrob Chemother; 2006 Sep 01; 58(3):697-700. PubMed ID: 16895941
    [Abstract] [Full Text] [Related]

  • 14. Emergence of rifampicin, tigecycline, and colistin-resistant Acinetobacter baumannii in Iran; spreading of MDR strains of novel International Clone variants.
    Bahador A, Taheri M, Pourakbari B, Hashemizadeh Z, Rostami H, Mansoori N, Raoofian R.
    Microb Drug Resist; 2013 Oct 01; 19(5):397-406. PubMed ID: 23768166
    [Abstract] [Full Text] [Related]

  • 15. Postantibiotic effects of tigecycline, colistin sulfate, and levofloxacin alone or tigecycline-colistin sulfate and tigecycline-levofloxacin combinations against Acinetobacter baumannii.
    Ozbek B, Sentürk A.
    Chemotherapy; 2010 Oct 01; 56(6):466-71. PubMed ID: 21088399
    [Abstract] [Full Text] [Related]

  • 16. In vitro activities of rifampin, colistin, sulbactam and tigecycline tested alone and in combination against extensively drug-resistant Acinetobacter baumannii.
    Dong X, Chen F, Zhang Y, Liu H, Liu Y, Ma L.
    J Antibiot (Tokyo); 2014 Sep 01; 67(9):677-80. PubMed ID: 25095805
    [Abstract] [Full Text] [Related]

  • 17. In vitro synergistic activity of tigecycline and colistin against XDR-Acinetobacter baumannii.
    Dizbay M, Tozlu DK, Cirak MY, Isik Y, Ozdemir K, Arman D.
    J Antibiot (Tokyo); 2010 Feb 01; 63(2):51-3. PubMed ID: 19942947
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A combination of tigecycline, colistin, and meropenem against multidrug-resistant Acinetobacter baumannii bacteremia in a renal transplant recipient: pharmacodynamic and microbiological aspects.
    Candel FJ, Calvo N, Head J, Sánchez A, Matesanz M, Culebras E, Barrientos A, Picazo J.
    Rev Esp Quimioter; 2010 Jun 01; 23(2):103-8. PubMed ID: 20559610
    [Abstract] [Full Text] [Related]

  • 20. Colistin and tigecycline susceptibility among multidrug-resistant Acinetobacter baumannii isolated from ventilator-associated pneumonia.
    Dizbay M, Altuncekic A, Sezer BE, Ozdemir K, Arman D.
    Int J Antimicrob Agents; 2008 Jul 01; 32(1):29-32. PubMed ID: 18539006
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.